Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

ONTX was reduced by Zacks  from a “acquire” ranking to a “hold” score in a research note released to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on uncovering and also developing small particle drug candidates to deal with cancer. The Company‘s items under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts also lately talked about the company. Noble Financial editioned a “purchase” score as well as provided a $11.00 rate purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day relocating ordinary cost of $2.90 and a two-hundred day moving ordinary cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, covering analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and also an adverse web margin of 8,294.27%. The company had revenue of $0.06 million during the quarter, contrasted to the agreement quote of $0.06 million. During the very same quarter in the previous year, the firm uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the current year.

A variety of hedge funds have actually lately bought and sold shares of ONTX. GSA Funding Allies LLP got a new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also other institutional investors own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the recognition and also development of oncology therapeutics. It focuses on finding and also creating small particle medicine candidates to treat cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more details regarding research offerings from Zacks Investment Research, go to Zacks.com.

This instant news alert was generated by narrative scientific research innovation and also financial information from Market in order to offer readers with the fastest as well as most precise reporting. This story was examined by Market’s content team prior to publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Before you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s top-rated and finest executing research experts and the stocks they advise to their customers on a daily basis. Market has actually recognized the five stocks that top experts are silently murmuring to their customers to get currently prior to the more comprehensive market catches on … as well as Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” score amongst experts, premier experts believe these five stocks are better gets.